Annovis Bio
Manufacturing · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
101 Lindenwood Dr Ste 225, Malvern, Penn...Phone Number
(484) 875-3192Website
www.annovisbio.comRevenue
<$5 MillionStock Symbol
ANVSIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Annovis Bio
Annovis Bio is a clinical stage drug platform company that develops pharmaceutical drugs to treat neurodegeneration. The company is headquartered in Malvern, Pennsylvania.Explore more
Annovis Bio Org Chart
MG
Chief Financial Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Annovis Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Annovis Bio has new funding data
Congratulate Masked Content for being promoted to Masked Content at Annovis Bio
Check out if Annovis Bio is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Annovis Bio recently announced quarterly report
Click to see if Annovis Bio had a recent Job posting/layoffs
Check if Annovis Bio has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Annovis Bio launches new products
Annovis Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Annovis Bio
Find more new buyers
Compare Similar Companies to Annovis Bio
Compare insights from companies similar to Annovis Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Annovis Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Annovis Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Annovis Bio.
Annovis Bio financials insights
Gather financial insights about Annovis Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Multiple Rounds
$3.3M
2013
Debt
$450K
2014
Unspecified
$500K
2015
Series A
$1.1M
Debt
$4.6M
2016
Private Equity
$799K
2025
Share Placement
$21M
Annovis Bio Tech Stack
A closer look at the technologies used by Annovis Bio
Most Recent Scoops
Earnings
Annovis Bio has reported net loss of $17.6 million for Q1 2026, compared to $5.5 million in Q1 2025.
Earnings, Finance
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Launch, Intellectual Property, Legal Affairs, Healthcare Technology
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
Earnings, Finance
Annovis Bio News & Media
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer.Annovis Bio Regains NYSE Listing Compliance
MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced today that it has regained compliance with the New York Stock Exchange (NYSE) continued listing standards.Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of 7,895,000 shares of its common stock and accompanying warrants to purchase up to 7,105,500 shares of common stock. The combinedAnnovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and (ii) accompanying warrants to purchase shares of common stock. Th
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Annovis Bio
Sign Up For FreeTo access detailed company insights
Annovis Bio is a clinical stage drug platform company that develops pharmaceutical drugs to treat neurodegeneration. The company is headquartered in Malvern, Pennsylvania.... Read More
